ATE414508T1 - Feste pharmazeutische darreichungsformen mit einem s1p rezeptoragonisten und einem zuckeralkohol - Google Patents

Feste pharmazeutische darreichungsformen mit einem s1p rezeptoragonisten und einem zuckeralkohol

Info

Publication number
ATE414508T1
ATE414508T1 AT04725895T AT04725895T ATE414508T1 AT E414508 T1 ATE414508 T1 AT E414508T1 AT 04725895 T AT04725895 T AT 04725895T AT 04725895 T AT04725895 T AT 04725895T AT E414508 T1 ATE414508 T1 AT E414508T1
Authority
AT
Austria
Prior art keywords
dosh
receptor agonist
sugar alcohol
solid pharmaceutical
forms containing
Prior art date
Application number
AT04725895T
Other languages
English (en)
Inventor
Tomoyuki Oomura
Madhusudhan Pudipeddi
Alan Royce
Colleen Ruegger
Masaki Sasaki
Tokuhiro Tamura
Original Assignee
Novartis Pharma Gmbh
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE414508(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Pharma Gmbh, Mitsubishi Pharma Corp filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE414508T1 publication Critical patent/ATE414508T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
AT04725895T 2003-04-08 2004-04-06 Feste pharmazeutische darreichungsformen mit einem s1p rezeptoragonisten und einem zuckeralkohol ATE414508T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46121503P 2003-04-08 2003-04-08

Publications (1)

Publication Number Publication Date
ATE414508T1 true ATE414508T1 (de) 2008-12-15

Family

ID=32326722

Family Applications (3)

Application Number Title Priority Date Filing Date
AT04725895T ATE414508T1 (de) 2003-04-08 2004-04-06 Feste pharmazeutische darreichungsformen mit einem s1p rezeptoragonisten und einem zuckeralkohol
ATA606/2004A AT501681B1 (de) 2003-04-08 2004-04-06 Feste orale pharmazeutische zusammensetzung enthaltend 2-amino-1,3-propandiole
AT0074408A AT504853A2 (de) 2003-04-08 2008-05-08 Organische verbindungen

Family Applications After (2)

Application Number Title Priority Date Filing Date
ATA606/2004A AT501681B1 (de) 2003-04-08 2004-04-06 Feste orale pharmazeutische zusammensetzung enthaltend 2-amino-1,3-propandiole
AT0074408A AT504853A2 (de) 2003-04-08 2008-05-08 Organische verbindungen

Country Status (42)

Country Link
US (11) US20060275357A1 (de)
EP (5) EP2316431B1 (de)
JP (3) JP5495467B2 (de)
KR (3) KR20050121712A (de)
CN (2) CN101797241B (de)
AR (3) AR043987A1 (de)
AT (3) ATE414508T1 (de)
AU (1) AU2004228929B2 (de)
BE (2) BE1015972A5 (de)
BR (1) BRPI0409250B8 (de)
CA (2) CA2521325C (de)
CL (2) CL2004000745A1 (de)
CY (3) CY1110260T1 (de)
DE (4) DE102004016947A1 (de)
DK (2) DK2316431T3 (de)
EC (1) ECSP056090A (de)
ES (3) ES2320767T3 (de)
FR (2) FR2854073B1 (de)
GB (1) GB2400318B (de)
GR (1) GR1005052B (de)
HK (3) HK1071685A1 (de)
HR (3) HRP20050886B1 (de)
HU (2) HUE028247T2 (de)
IL (3) IL170888A (de)
IS (2) IS2682B (de)
IT (1) ITMI20040682A1 (de)
LU (1) LU91867I2 (de)
MA (1) MA27729A1 (de)
MX (1) MXPA05010860A (de)
MY (1) MY141249A (de)
NO (4) NO329332B1 (de)
NZ (3) NZ542622A (de)
PE (5) PE20131352A1 (de)
PL (2) PL1613288T3 (de)
PT (1) PT1613288E (de)
RU (5) RU2358716C2 (de)
SG (1) SG175449A1 (de)
SI (2) SI1613288T1 (de)
TN (1) TNSN05256A1 (de)
TW (1) TWI332847B (de)
WO (1) WO2004089341A1 (de)
ZA (1) ZA200507394B (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2574664C (en) * 2004-07-30 2013-01-15 Novartis Ag Compound formulations of 2-amino-1,3-propanediol compounds
CN1891212B (zh) * 2005-07-07 2010-10-13 马启明 一种口服制剂及其制备方法
PL1926483T3 (pl) * 2005-09-09 2011-05-31 Novartis Ag Leczenie chorób autoimmunologicznych
KR101274417B1 (ko) 2005-11-09 2013-06-17 프로테올릭스, 인코퍼레이티드 효소 저해를 위한 화합물
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
CA2657213C (en) 2006-06-19 2017-01-03 Proteolix, Inc. Peptide epoxyketones for proteasome inhibition
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
EP1923055A1 (de) * 2006-09-26 2008-05-21 Novartis AG Gefriergetrocknete pharmazeutische Zusammensetzung mit einem S1P Agonisten oder Modulator
EP1923058A1 (de) * 2006-09-26 2008-05-21 Novartis AG Umhüllte pharmazeutische Zusammensetzung mit einem S1P Agonisten oder Modulator
EP1923054A1 (de) * 2006-09-26 2008-05-21 Novartis AG Schnell zerfallende pharmazeutische Zusammensetzung mit einem S1P Agonisten oder Modulator
EP1905434A1 (de) * 2006-09-26 2008-04-02 Novartis AG Organische S1P Rezeptor Agonist Verbindungen und ihre therapeutische Verwendung
AU2011235934A1 (en) * 2006-09-26 2011-11-03 Novartis Ag Pharmaceutical compositions comprising an S1P modulator
WO2008037421A2 (en) * 2006-09-26 2008-04-03 Novartis Ag Pharmaceutical compositions comprising an s1p modulator
WO2008124210A1 (en) * 2007-02-14 2008-10-16 Emory University Methods and compositions for treating or preventing infection using leukocyte sequestration agents
SG179497A1 (en) * 2007-03-29 2012-04-27 Daiichi Sankyo Co Ltd Pharmaceutical composition
MY173938A (en) 2007-10-04 2020-02-27 Onyx Therapeutics Inc Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
AU2012216630B2 (en) * 2007-10-12 2015-01-22 Novartis Ag Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators
EP3733162A1 (de) * 2007-10-12 2020-11-04 Novartis AG Zusammensetzung mit sphingosin-1-phosphat (s1p)-rezeptormodulatoren
JP5534645B2 (ja) * 2008-01-11 2014-07-02 日医工株式会社 無包装状態において安定性に優れた塩酸サルポグレラート含有経口投与製剤
TW200946105A (en) 2008-02-07 2009-11-16 Kyorin Seiyaku Kk Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient
CN104800208A (zh) 2008-03-17 2015-07-29 埃科特莱茵药品有限公司 选择性s1p1受体激动剂的给药方案
MX2010014209A (es) * 2008-06-20 2011-02-21 Merck Patent Gmbh Matriz de comprimidos de compresion directa y rapida desintegracion.
EP3011958A1 (de) 2008-06-20 2016-04-27 Novartis AG Pädiatrische zusammensetzungen zur behandlung von multipler sklerose
PT2334202E (pt) * 2008-09-04 2012-02-28 Cargill Inc Fabrico de comprimidos de eritritol
PE20120059A1 (es) 2008-10-21 2012-02-27 Onyx Therapeutics Inc Combinaciones farmaceuticas con epoxicetonas peptidicas
AU2009315735B2 (en) 2008-11-11 2013-01-10 Novartis Ag Salts of fingolimod
AU2013100533B4 (en) * 2008-11-11 2013-12-12 Novartis Ag Crystalline forms of fingolimod HCL
CA2743232C (en) 2008-11-11 2015-12-29 Novartis Ag Crystalline forms of fingolimod hcl
SI2371830T1 (sl) 2008-12-17 2014-01-31 Daiichi Sankyo Company, Limited Postopek za pridobivanje diaminskih derivatov
WO2010082531A1 (ja) 2009-01-13 2010-07-22 第一三共株式会社 活性化血液凝固因子阻害剤
JP5666424B2 (ja) 2009-03-10 2015-02-12 第一三共株式会社 ジアミン誘導体の製造方法
JP5652879B2 (ja) 2009-03-13 2015-01-14 第一三共株式会社 光学活性なジアミン誘導体の製造方法
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
ES2605034T3 (es) * 2009-06-18 2017-03-10 Daiichi Sankyo Company, Limited Composición farmacéutica con solubilidad mejorada
US9675566B2 (en) 2009-07-16 2017-06-13 Pathologica Llc Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
WO2011060179A1 (en) 2009-11-13 2011-05-19 Onyx Therapeutics, Inc Use of peptide epoxyketones for metastasis suppression
MA34133B1 (fr) 2010-03-01 2013-04-03 Onyx Therapeutics Inc Composes pour inhibiteurs de l'immunoproteasome
JP5390014B2 (ja) 2010-03-19 2014-01-15 第一三共株式会社 抗凝固剤の溶出改善方法
JP5692873B2 (ja) 2010-03-19 2015-04-01 第一三共株式会社 ジアミン誘導体の結晶およびその製造方法
EP2560619A2 (de) * 2010-04-22 2013-02-27 Ratiopharm GmbH Verfahren zur herstellung einer oralen darreichungsform mit fingolimod
WO2012002538A1 (ja) 2010-07-02 2012-01-05 第一三共株式会社 光学活性ジアミン誘導体の塩の製造方法
WO2012070059A1 (en) 2010-11-25 2012-05-31 Shilpa Medicare Limited Fingolimod polymorphs and their processes
PT2665471T (pt) 2011-01-19 2018-03-21 Pathologica Llc Formas de dosagem farmacêutica orais de libertação controlada que compreendem mgbg
JO3177B1 (ar) * 2011-04-01 2018-03-08 Novartis Ag تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول
EP2739272A1 (de) 2011-08-01 2014-06-11 Teva Pharmaceutical Industries Ltd. Verfahren für die zubereitung von pharmazeutischen zusammensetzungen mit fingolimod
US9402907B2 (en) 2011-08-10 2016-08-02 Daiichi Sankyo Company, Limited Pharmaceutical composition containing diamine derivative
WO2013091704A1 (en) 2011-12-22 2013-06-27 Synthon Bv Pharmaceutical composition comprising fingolimod
RU2482842C1 (ru) * 2012-04-26 2013-05-27 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний (варианты) и способ ее получения
RU2506949C1 (ru) * 2012-06-13 2014-02-20 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
WO2014011695A2 (en) 2012-07-09 2014-01-16 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
RU2496486C1 (ru) * 2012-07-11 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
EP3831372A1 (de) 2013-01-08 2021-06-09 Pathologica LLC Mitoguazon zur verhinderung des rückfalls oder des fortschreitens der multiplen sklerose
WO2014141298A2 (en) * 2013-03-11 2014-09-18 Astron Research Limited Stable pharmaceutical composition of fingolimod
WO2014175287A1 (ja) * 2013-04-26 2014-10-30 国立大学法人 京都大学 脳動脈瘤の形成および／または増大の抑制若しくは縮小用医薬組成物
WO2013190151A1 (en) * 2013-05-13 2013-12-27 Synthon B.V. Pharmaceutical composition comprising fingolimod
JP6316422B2 (ja) * 2013-07-29 2018-04-25 アイザント ドラッグ リサーチ ソリューションズ プライベート リミテッドＡｉｚａｎｔ Ｄｒｕｇ Ｒｅｓｅａｒｃｈ Ｓｏｌｕｔｉｏｎｓ Ｐｖｔ Ｌｔｄ フィンゴリモドの医薬組成物
RU2530626C1 (ru) * 2013-10-21 2014-10-10 Ооо "Валента-Интеллект" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
WO2016026461A1 (en) * 2014-08-22 2016-02-25 Sunshine Lake Pharma Co., Ltd. Solid composition of fingolimod and preparation thereof
WO2016042493A1 (en) * 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Pharmaceutical compositions of fingolimod
CA2974375A1 (en) * 2015-01-20 2016-07-28 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
CA2973540A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
RU2577230C1 (ru) * 2015-04-09 2016-03-10 Общество с ограниченной ответственностью "Лонг Шенг Фарма Рус" Способ получения капсул финголимода гидрохлорида
US9690975B2 (en) * 2015-05-28 2017-06-27 Axogen Corporation Quantitative structural assay of a nerve graft
WO2018178744A1 (en) 2017-03-29 2018-10-04 Deva Holding Anonim Sirketi Stable formulations of fingolimod
GR1009654B (el) 2018-08-31 2019-11-18 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει εναν ανοσοτροποποιητικο παραγοντα και μεθοδος για την παρασκευη αυτου
DE102018217334A1 (de) * 2018-10-10 2020-04-16 Harbins Ruhr Bioscience, Inc. Sphingoid-Base und/oder Wirkstoff zur Verwendung bei der Prophylaxe und/oder Therapie einer viralen Infektion und/oder viralen Infektionskrankheit oder der Desinfektion, Nahrungsmittel/Nahrungsergänzungsmittel, Futtermittel/Futterergänzungsmittel und Pflanzenschutzmittel
EP4181906A1 (de) 2020-07-16 2023-05-24 Harbins Ruhr Bioscience, Inc. Sphingoidverbindungen zur verwendung bei der prophylaxe und/oder therapie von coronaviridae-infektionen

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7607683A (nl) * 1976-07-12 1978-01-16 Akzo Nv Werkwijze ter bereiding van nieuwe peptiden en peptide-derivaten en de toepassing hiervan.
US4110332A (en) * 1977-05-05 1978-08-29 Chevron Research Company 1-Triorganostannyl-3-organothio-4-substituted-1,2,4-delta2 -triazolidin-5-ones
US4559153A (en) 1983-10-25 1985-12-17 Phillips Petroleum Company Metal working lubricant
US5112616A (en) * 1988-11-30 1992-05-12 Schering Corporation Fast dissolving buccal tablet
JP2841857B2 (ja) * 1990-11-29 1998-12-24 田辺製薬株式会社 長期間安定な経口用医薬製剤
WO1994008943A1 (en) 1992-10-21 1994-04-28 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
EP0778263B1 (de) 1994-08-22 2002-01-09 Welfide Corporation Benzolderivate und deren medizinische verwendung
IL121625A (en) 1995-12-28 2001-09-13 Welfide Corp Preparation containing 2 - amino - 2 - (-2 (-4-octylphenyl) ethyl) propane - 1, 3, - dial for local topical use
US6476004B1 (en) * 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
JP2002241272A (ja) 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
JPH11209277A (ja) * 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
GB9624038D0 (en) 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
EP2030614A1 (de) * 1997-02-27 2009-03-04 Novartis AG Pharmazeutische Zusammensetzung enthaltend 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol und ein Lecithin
PT1319651E (pt) * 1997-04-04 2005-09-30 Mitsubishi Pharma Corp Composto 2-aminopropano-1,3-diol, sua utilizacao farmaceutica e seus intermediarios sinteticos
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
JP3545595B2 (ja) 1998-04-01 2004-07-21 花王株式会社 スフィンゴ糖脂質の製造法
JP4627356B2 (ja) 1999-06-30 2011-02-09 松森　　昭 ウイルス性心筋炎の予防または治療薬剤
WO2001003739A1 (fr) * 1999-07-12 2001-01-18 Ono Pharmaceutical Co., Ltd. Inhibiteurs de fibrose contenant comme ingredient actif l'agoniste du recepteur de sphingosine-1-phosphate ou la sphingosine-1-phosphate
CN1267429C (zh) 2000-07-13 2006-08-02 三共株式会社 氨基醇衍生物
AU8533101A (en) * 2000-08-31 2002-03-13 Merck & Co Inc Phosphate derivatives as immunoregulatory agents
US6953332B1 (en) 2000-11-28 2005-10-11 St. Jude Medical, Inc. Mandrel for use in forming valved prostheses having polymer leaflets by dip coating
SK11942003A3 (sk) 2001-03-26 2004-03-02 Novartis Ag Deriváty 2-aminopropanolu, ich použitie a farmaceutická kompozícia, ktorá ich obsahuje
US7521192B2 (en) * 2001-04-18 2009-04-21 Rigel Pharmaceuticals, Inc. EDG: modulators of lymphocyte activation and migration
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
WO2003020313A1 (fr) 2001-09-04 2003-03-13 Ono Pharmaceutical Co., Ltd. Medicaments contre les maladies respiratoires renfermant un agent de regulation du recepteur de la sphingosine-1-phosphate
CA2461212C (en) 2001-09-27 2010-08-17 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivatives, salts thereof and immunosuppressive agents using the same
WO2003029184A1 (fr) 2001-09-27 2003-04-10 Kyorin Pharmaceutical Co., Ltd. Derive d'ether de diaryle, son sel d'addition et son immunosuppresseur
DE60329073D1 (de) 2002-01-18 2009-10-15 Merck & Co Inc Edg-rezeptoragonisten
CA2472713C (en) 2002-01-18 2011-07-19 Merck & Co., Inc. N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as edg receptor agonists
AU2003214873A1 (en) 2002-01-18 2003-09-02 Ceretek Llc Methods of treating conditions associated with an edg receptor
WO2003061567A2 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists
DK1772145T3 (da) * 2004-07-16 2011-05-30 Kyorin Seiyaku Kk Fremgangsmåde til effektiv anvendelse af medicin og fremgangsmåde til forebyggelse af bivirkninger

Also Published As

Publication number Publication date
IL197578A0 (en) 2011-07-31
NO329332B1 (no) 2010-09-27
NZ592339A (en) 2012-09-28
NZ542622A (en) 2009-01-31
AR043987A1 (es) 2005-08-17
DK1613288T3 (da) 2009-03-23
IE20040246A1 (en) 2004-12-15
DK2316431T3 (en) 2016-01-11
MA27729A1 (fr) 2006-01-02
AR078781A2 (es) 2011-11-30
US20140011885A1 (en) 2014-01-09
HRP20050886B1 (en) 2011-01-31
RU2005134173A (ru) 2006-09-10
NO20055231L (no) 2006-01-09
PL2316431T3 (pl) 2016-09-30
PE20130200A1 (es) 2013-03-09
IL242037A0 (en) 2015-11-30
PE20150676A1 (es) 2015-05-17
EP2008650A2 (de) 2008-12-31
BRPI0409250B1 (pt) 2017-07-11
JP2004307506A (ja) 2004-11-04
AU2004228929B2 (en) 2008-02-07
MY141249A (en) 2010-03-31
MXPA05010860A (es) 2006-05-25
KR20050121712A (ko) 2005-12-27
CY1117071T1 (el) 2017-04-05
BE2011C030I2 (de) 2023-03-07
GR20040100121A (el) 2004-12-17
HRP20100601A2 (hr) 2011-03-31
CY2011013I1 (el) 2014-04-09
EP1613288A1 (de) 2006-01-11
TW200503784A (en) 2005-02-01
GB2400318A (en) 2004-10-13
CA2521325A1 (en) 2004-10-21
US20110105620A1 (en) 2011-05-05
BE1015972A5 (fr) 2005-12-06
CL2011000450A1 (es) 2011-11-25
HK1155647A1 (en) 2012-05-25
EP2319502A1 (de) 2011-05-11
IS8885A (is) 2010-02-25
US20190175527A1 (en) 2019-06-13
EP2316431B1 (de) 2015-09-30
CA2521325C (en) 2010-09-14
NO20100250L (no) 2006-01-09
KR20110005320A (ko) 2011-01-17
US20200237690A1 (en) 2020-07-30
DE122011100047I1 (de) 2011-12-15
RU2009105403A (ru) 2010-08-27
CN1767819A (zh) 2006-05-03
TWI332847B (en) 2010-11-11
ES2228282A1 (es) 2005-04-01
RU2010146697A (ru) 2012-05-27
PE20050396A1 (es) 2005-07-05
IL170888A (en) 2010-06-16
FR2854073B1 (fr) 2008-03-14
JP2013177404A (ja) 2013-09-09
JP5495467B2 (ja) 2014-05-21
LU91867I9 (de) 2019-01-03
JP5543298B2 (ja) 2014-07-09
GB0407819D0 (en) 2004-05-12
ZA200507394B (en) 2007-03-28
IS2682B (is) 2010-10-15
HRP20050886A2 (en) 2006-11-30
NO2011016I1 (no) 2011-09-19
US20080311188A1 (en) 2008-12-18
FR2854073A1 (fr) 2004-10-29
AT501681A1 (de) 2006-10-15
US20060275357A1 (en) 2006-12-07
FR11C0036I1 (fr) 2011-10-14
DE602004017847D1 (de) 2009-01-02
CA2707750A1 (en) 2004-10-21
RU2010147000A (ru) 2012-08-10
NO20131287L (no) 2006-01-09
ES2320767T3 (es) 2009-05-28
NZ586280A (en) 2011-12-22
HUE028247T2 (en) 2016-12-28
CL2004000745A1 (es) 2005-02-11
NO2011016I2 (no) 2012-08-27
CY2011013I2 (el) 2014-04-09
HK1071685A1 (en) 2005-07-29
SI1613288T1 (sl) 2009-04-30
KR101367574B1 (ko) 2014-02-25
PL1613288T3 (pl) 2009-07-31
US20140255497A1 (en) 2014-09-11
NO20055231D0 (no) 2005-11-07
NO334116B1 (no) 2013-12-16
AT504853A2 (de) 2008-08-15
FR11C0036I2 (fr) 2023-12-29
CN1767819B (zh) 2010-07-28
LU91867I2 (fr) 2011-11-08
CY1110260T1 (el) 2014-04-09
EP1613288B1 (de) 2008-11-19
WO2004089341A1 (en) 2004-10-21
PE20090743A1 (es) 2009-07-17
AT501681B1 (de) 2012-04-15
CN101797241A (zh) 2010-08-11
RU2358716C2 (ru) 2009-06-20
RU2475236C2 (ru) 2013-02-20
US8324283B2 (en) 2012-12-04
PE20131352A1 (es) 2013-11-14
US20170290787A1 (en) 2017-10-12
RU2012148593A (ru) 2014-05-20
PT1613288E (pt) 2009-02-25
DE102004016947A1 (de) 2004-10-21
BRPI0409250A (pt) 2006-03-28
HUS1100016I1 (hu) 2016-08-29
US20090203798A1 (en) 2009-08-13
EP2008650A3 (de) 2011-04-27
CN101797241B (zh) 2013-03-27
EP2316431A1 (de) 2011-05-04
TNSN05256A1 (en) 2007-07-10
IS8114A (is) 2005-11-01
AR078782A2 (es) 2011-11-30
SI2316431T1 (sl) 2016-04-29
IL197578A (en) 2015-10-29
ITMI20040682A1 (it) 2004-07-06
ES2556947T3 (es) 2016-01-21
BRPI0409250B8 (pt) 2022-01-18
NO335120B1 (no) 2014-09-22
ES2228282B1 (es) 2006-02-16
US20130108675A1 (en) 2013-05-02
GB2400318B (en) 2005-08-10
DE202004021680U1 (de) 2010-04-22
US20220031609A1 (en) 2022-02-03
HRP20100601B1 (hr) 2016-12-02
KR20120101148A (ko) 2012-09-12
ECSP056090A (es) 2006-03-01
SG175449A1 (en) 2011-11-28
EP2769713A1 (de) 2014-08-27
GR1005052B (el) 2005-11-30
HRP20100600A2 (hr) 2011-03-31
JP2011006461A (ja) 2011-01-13
RU2475237C2 (ru) 2013-02-20
HK1091114A1 (en) 2007-01-12
AU2004228929A1 (en) 2004-10-21

Similar Documents

Publication Publication Date Title
ATE414508T1 (de) Feste pharmazeutische darreichungsformen mit einem s1p rezeptoragonisten und einem zuckeralkohol
DE602005012107D1 (de) Pharmazeutische formulierungen mit einem antibioti
DE602006010088D1 (de) Pharmazeutische formulierungen mit einem langzeit-beta-2-agonisten zur verabreichung durch verneblung
ZA200602260B (en) A pharmaceutical composition comprising a P2X7 receptor antagonist and a nonsteroidal anti-inflammatory drug
DE602004016967D1 (de) Flüssige pharmazeutische palonosetronformulierungen
ATE400254T1 (de) Pharmazeutische nanoparticuläre zubereitung eines tachikaninrezeptorantagonisten
DE602004010785D1 (de) 2-cyanopyrrolopyrimidine und deren pharmazeutische verwendung
DE60308372D1 (de) Dosierungsverabreichungsvorrichtung
DE60312049D1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen amorphen wirkstoff
ATE362771T1 (de) Pharmazeutische iressa zusammensetzung enthaltend ein wasserlösliches cellulosederivat
DE60317803D1 (de) Pharmazeutische zusammensetzungen enthaltend cyclosporin zur oralen verabreichung
DE602005021475D1 (de) Magenresistente pharmazeutische dosierform mit n-(2-(2-phthalimidoethoxy)-acetyl)-l-alanyl-d-glutaminsäure (lk-423)
ATE551051T1 (de) Orales arzneimittelabgabesystem
DE60336999D1 (de) Melatonin enthaltende pharmazeutische formulierung
DE60306747D1 (de) Perindopril enthaltende pharmazeutische zusammensetzung mit oraler dispersion
IL172250A0 (en) Improved pharmaceutical drug candidates and methods for preparation thereof
ATE422889T1 (de) Pharmazeutische formulierung mit einem pyrimidin- a-on-derivat und einem überzug aus einem magensaftresistenten polymer
ATE546141T1 (de) Pharmazeutisches injektionspräparat
ATE373488T1 (de) Antimykobakterielle pharmazeutische zusammensetzung mit einem arzneimittel gegen tuberkulose
ITMI20020921A0 (it) Dispositivo per la sommistrazione di farmaci
ITMI20040922A1 (it) Dispositivo per tamponare e separare contenitori farmaceutici
ATE428416T1 (de) Feste pharmazeutische zubereitung enthaltend (r)- (-)-2-ä5-(4-fluorophenyl)-3- pyridylmethylaminomethylü-chroman
DE602004030921D1 (de) Pharmazeutische zusammensetzung
ES1055546Y (es) Contenedor-dosificador para pastillas farmaceuticas.
ITMI20031947A1 (it) Dispositivo per pesare specialmente contenitori farmaceutici